BIAF vs. GH: Which Cancer Detection Stock Is the Better Buy Now?

The cancer diagnostics industry is evolving rapidly as advances in biotechnology, data analytics and precision medicine continue to reshape how diseases are detected and managed. Within this landscape, bioAffinity Technologies, Inc. BIAF and Guardant Health, Inc. GH represent two distinct approaches to cancer diagnostics and molecular testing. While both companies operate in the broader oncology diagnostics space, their strategies differ in technological focus, product scope and market positioning.

bioAffinity is primarily focused on developing non-invasive diagnostic tests aimed at the early detection of lung cancer and other lung diseases. The company’s platform combines flow cytometry with automated data analysis supported by machine learning to identify cell populations associated with disease. Its lead product, CyPath Lung, analyzes sputum samples to detect cellular characteristics that may indicate the presence of lung cancer, offering physicians an additional diagnostic tool to evaluate patients at elevated risk.

Guardant Health, by contrast, operates a broader precision oncology platform built around blood- and tissue-based genomic testing. The company offers a range of molecular diagnostics designed to support cancer care across multiple stages, including early detection, therapy selection and disease monitoring. Its portfolio includes liquid biopsy tests that analyze circulating tumor DNA to help physicians make treatment decisions and monitor disease progression.

With differing technological approaches and product strategies, the question is whether bioAffinity’s targeted lung cancer diagnostic platform or Guardant Health’s broader precision oncology testing portfolio presents the more compelling outlook. Let’s take a closer look.

Stock Performance & Valuation: BIAF vs. GH

BIAF (down 37.6%) has underperformed GH (down 10.7%) over the past three months. In the past year, bioAffinity stock has plunged 90.9% against Guardant Health stock’s surge of 131.6%.

Meanwhile, BIAF is trading at a trailing 12-month price-to-sales (P/S) ratio of 0.2X, below its median of 1.1X over the past two years. GH’s trailing P/S multiple sits at 12.2X, above its last two-year median of 6.7X. While BIAF appears cheap when compared with the Zacks Medical sector average of 2.6X, GH seems to be expensive.

Factors Driving bioAffinity Stock

One of the primary drivers for bioAffinity is the increasing clinical adoption of its flagship diagnostic test, CyPath Lung. The company is focused on commercializing this non-invasive test designed to help detect early-stage lung cancer in patients at high risk for the disease. Physician interest in the test has been rising as it provides additional diagnostic insight when evaluating suspicious pulmonary nodules and can complement existing imaging-based screening methods. Increasing physician confidence and broader use across healthcare settings have supported higher test volumes and stronger testing-related revenue growth, indicating expanding market traction for BIAF’s core product.

Another factor supporting the stock is the growing body of clinical evidence demonstrating the utility of CyPath Lung in real-world medical decision-making. Case studies have shown that the test can help physicians better assess cancer risk in patients with suspicious lung findings, potentially reducing the need for invasive diagnostic procedures such as biopsies. By providing additional objective data for risk stratification, the test helps guide treatment decisions and supports surveillance strategies in certain cases. Continued publication of clinical findings and real-world outcomes strengthens the credibility of the technology and may support broader clinical adoption over time.

Beyond its current commercial test, bioAffinity is advancing a broader diagnostic platform built around flow cytometry and AI-driven data analysis. The company is leveraging this platform to develop additional diagnostics aimed at lung diseases such as asthma and chronic obstructive pulmonary disease. Early research suggests that the technology could help identify biological markers that guide therapy selection and disease monitoring. The ability to extend the underlying technology beyond lung cancer diagnostics provides a pathway for future product development and potential expansion into additional areas of respiratory disease management.

Factors Driving Guardant Health Stock

Guardant Health is strengthening its position in the rapidly growing liquid biopsy market with a broad portfolio of blood- and tissue-based tests used across the cancer care continuum. Its flagship products, including Guardant360 for therapy selection and Guardant Reveal for minimal residual disease detection, help physicians identify actionable mutations and monitor recurrence using non-invasive blood samples. GH’s integrated Smart Platform combines genomic, epigenomic and AI-driven analytics to improve test sensitivity and clinical insights, supporting adoption among oncologists and health systems. Continued product upgrades and new applications across therapy selection and monitoring are helping drive increasing clinical utilization and test volumes.

Another major growth driver is the commercial rollout of Shield, Guardant Health’s blood-based colorectal cancer screening test. The test offers a non-invasive alternative to traditional screening methods and has received FDA approval, Medicare coverage and inclusion in national colorectal cancer screening guidelines. Expanding commercial infrastructure, payer coverage and outreach initiatives are helping accelerate adoption. Efforts such as nationwide screening programs are also improving patient access and awareness, supporting broader use of the test across eligible populations.

Guardant Health’s expanding product portfolio and increasing test utilization are translating into strong commercial growth. Revenue has been rising across oncology testing, screening and biopharma partnerships, supported by higher testing volumes and broader clinical adoption. Strategic collaborations with pharmaceutical companies and growing demand for precision oncology data are further strengthening the company’s ecosystem and monetization opportunities. Together, these factors position Guardant Health to capitalize on the expanding precision oncology and early cancer detection markets while scaling its commercial platform.

Choose GH Over BIAF Now

While both bioAffinity and Guardant Health operate in the cancer diagnostics space, their recent stock performance reflects very different investor sentiment. Guardant Health has posted strong gains over the past year, highlighting growing confidence in its expanding product portfolio and increasing adoption of its precision oncology tests. The stock’s current valuation suggests that investors are already pricing in continued growth from its screening and diagnostic platforms.

bioAffinity, in contrast, has seen a sharp decline in its share price, indicating more cautious market sentiment. The stock now trades at a deeply discounted level relative to its historical range and the broader medical sector. While this may suggest potential upside if commercialization efforts gain traction, it also reflects uncertainty surrounding BIAF’s growth visibility.

For investors weighing which cancer detection stock is the better buy now, the choice comes down to stability versus speculative recovery. Guardant Health offers stronger momentum and clearer growth prospects, while bioAffinity represents a higher-risk turnaround opportunity. Given its stronger fundamentals and market traction, Guardant Health currently appears to be the more compelling investment option.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research